NCT03630809终止2 期
Immune Response Surveillance and Potential Booster Vaccines for Patients Who Have Received HER2-pulsed DC1 Vaccine
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 2
- 主要终点
- HER2 DC1 Vaccine Regimen
研究概览
简要总结
The purpose of this study is to learn more about how to treat patients with a diagnosis of diagnosis of Human Epidermal Growth Factor Receptor 2/neu (HER-2/neu) positive breast cancer in the past, who were previously treated with HER-2/neu-directed dendritic cells (DC) vaccines.
There is evidence that the use of anti-HER2 dendritic cell (DC) study vaccines could improve response to breast cancer therapy and be an important step in the prevention of recurrence.
This study will use a Dendritic Cell Type 1 (DC1) vaccine which is a HER2-sensitized dendritic cell (DC) study vaccine. Dendritic cells are immune cells that can tell the participant's immune system to fight infection. This study vaccine will be made from the participant's blood cells collected from a procedure called leukapheresis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Patients with a diagnosis of nonmetastatic or metastatic breast cancer in complete clinicla response classic HER2pos (ie, IHC 3+ or FISHpos) breast cancer (BC) who have previously been vaccinated with DC1 HER2-pulsed vaccines on any of several prior clinical trials for ductal carcinoma in situ (DCIS) or inflammatory breast cancer (IBC) are eligible; however, we also allowed HER2 2+ patients in many of these prior trials and they will also be allowed to participate in this trial. Note: HER2pos BC is defined by tumor tissue HER2 overexpression and or tumor HER2 amplification. The lack of HER2 overexpression by IHC is defined as 0 or 1+ whereas overexpression is defined as 3+. In the event of equivocal IHC, 2+, the tumor must be gene-amplified by fluorescent in situ hybridization (FISH) performed upon the primary tumor or metastatic lesion (ratio > 2 and HER2 copy number > 4 define HER2negdisease).
- •Patients with nonmetastatic HER posBC must have completed all standard-of-care treatment for nonmetastatic BC (e.g., surgery, chemotherapy, radiation therapy, and HER2-targeted therapy). Note: antiestrogen therapy is permitted while on trial. Note: antiestrogen therapy is permitted while on trial.
- •Patients with diagnosis of metastatic HER2 pos breast cancer must have complete tumor response to current treatment per RECIST 1.1 and completed all standard-of-care chemotherapy. Note: maintenance treatment with approved HER2-targeted agents and/or antiestrogen therapy is permitted while on trial.
- •Age ≥ 18 years.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or
- •Participants must have normal organ and marrow function within 2 weeks of registration.
- •For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose.
- •Must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.
排除标准
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congenital prolonged QT syndrome, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- •Uncontrolled congenital or acquired immune deficiency that is requiring treatment that would interfere with study treatment will not be allowed on study. Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed. Patients who have received systemic corticosteroids ≤ 30 days prior to starting study drug will be excluded.
- •No other prior malignancy is allowed except for the following:
- •Adequately treated basal cell or squamous cell skin cancer
- •In situ cervical cancer
- •Any other cancer from which the patient has been disease free for at least 3 years.
- •Pregnant or breast feeding.
- •Known to be HIV positive.
- •Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared.
- •Major surgery within 4 weeks of initiation of study drug.
- •Have not recovered to ≤ Grade 1 or tolerable Grade 2 adverse events (AEs) due to agents administered ≥ 28 days earlier, as documented by the treating investigator.
- •Currently enrolled in any other clinical protocol or investigational trial that involves administration of experimental therapy and/or therapeutic devices, or investigational drug. Note: patients enrolled on another HER2 vaccine trial but not receiving active therapy can enroll in this study.
- •Not able to comply with the treatment schedule and study procedures for any reason.
结局指标
主要结局
HER2 DC1 Vaccine Regimen
时间窗: Up to 16 months
Investigators will assess the feasibility of participants receiving the six-booster regimen if 11/15 randomized to Arm D complete all 6 booster injections.
次要结局
- HER2 Immunity with 3 Booster Regimen at 18 months(At 18 months after first dose)
- Rate of Treatment Emergent Adverse Events of 6 Dose Regimen(Up to 5 years)
- Overall Survival(Up to 5 Years)
- Disease Free Survival(Up to 5 Years)
- Progression Free Survival(Up to 5 Years)
- HER2 Immunity with 6 Booster Regimen at 18 months(At 18 months after first dose)
- HER2 Immunity with 3 Booster Regimen at 10 months(At 10 months after first dose)
- HER2 Immunity with 6 Booster Regimen at 10 months(At 10 months after first dose)
- Rate of Treatment Emergent Adverse Events of 3 Dose Regimen(Up to 5 years)
研究者
研究点 (2)
Loading locations...
相似试验
Enrolling By Invitation
不适用
The Therapeutic Effect of Immunotherapy in Patients With Advanced Lung Squamous CarcinomaSquamous Cell Lung CancerNCT06647836Wuhan Union Hospital, China1,000
招募中
不适用
Evaluation of Patients With Immune Function AbnormalitiesChronic Granulomatous Disease (CGD)X-Linked Severe Combined Immune Deficiency (XSCID)Leukocyte Adhesion Deficiency 1 (LAD)Graft Versus Host Disease (cGvHD)NCT00128973National Institute of Allergy and Infectious Diseases (NIAID)3,500
已完成
不适用
Selecting Specific Bio-markers and Researching Mechanisms of Immune Regulation From Inhalation Injury and Traumatic Lung Injury Based on Single Cell Sequencing TechnologyTraumatic Lung InjuryInhalation InjuryNCT05718830Changhai Hospital21
Unknown
不适用
Multi Dimensional Precise Exploration of Immunoconsolidation Therapy for Locally Advanced NSCLC After Chemo-radiotherapyNSCLCChemoradiotherapyctDNANCT04741633Fudan University25
已完成
不适用
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer ImmunotherapyCancerSkin DiseaseImmunotherapyPatients With Solid Tumors Receiving Immunotherapy With an ICI Will be Randomized to Participate in an SDoH and Side Effects Navigation Program vs. ControlNCT04283539National Jewish Health255